coagulation factor viia

PCI-27483 is an activated coagulation factor VIIa inhibitor with antithrombotic effects in a baboon model of arterial thrombosis. It also inhibits the growth of BxPC3 xenografts by 42% and 85% at doses of 60 and 90 mg/kg, respectively.

BMS-593214 is an active site-directed factor (F) VIIa inhibitor that exhibits antithrombotic and antihaemostatic properties. It acts as a direct competitive inhibitor of human FVIIa and a non-competitive inhibitor of FVIIa-activated substrate FX. Additionally, BMS-593214 effectively prevents electroinduced carotid artery thrombosis (AT) and wire-induced vena cava thrombosis (VT).

BCX-3607 is an orally active tissue factor/factor VIIa (TF-FVIIa) inhibitor with an IC50 of 4 nM. By inhibiting the TF-FVIIa complex, it effectively blocks the extrinsic coagulation pathway and significantly prolongs prothrombin time (PT). BCX-3607 exhibits higher selectivity for TF-FVIIa over other serine proteases like thrombin and FXa. It reduces thrombus weight and inflammation, offering dual anti-thrombotic and anti-inflammatory effects. BCX-3607 is applicable in research on thrombosis-related diseases.

Anpocogin, a variant of the Ancyclostoma canium nematode anticoagulant protein c2 with an added C-terminal P85, is synthesized in Pichia pastoris and functions as an anticoagulant agent [1].Recombinant nematode anticoagulant protein c2 (rNAPc2) is a potent inhibitor of serine protease factor VIIa and its cell-associated cofactor tissue factor FVIIa/TF, a key physiological initiator of blood coagulation, with potential efficacy in the treatment of disseminated intravascular coagulopathy and venous and arterial thrombosis.

E-76 is a peptide with anticoagulant activity that inhibits blood coagulation by specifically binding to the exogenous coagulation factor VIIa (FVIIa). It is utilized in the study of blood coagulation-related diseases.

HumanFactor VIIa is a vitamin K-dependent serine protease involved in the blood coagulation process. It has the ability to activate coagulation factor X, which in turn converts prothrombin into thrombin, leading to the transformation of fibrinogen into fibrin and resulting in the formation of blood clots. HumanFactor VIIa holds potential for improving hemophilia.